ADVERTISEMENT
Numinus Partners With MAPS on Psychedelic Experiential Training Initiative
Numinus Wellness announced on Thursday that it is partnering with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support experiential opportunities for practitioners as part of a clinical study.
Pending the approval of a clinical trial application (CTA) submitted to Health Canada, the nation’s governing body for healthcare, the MDMA-assisted therapy experiential opportunity would be available exclusively through Numinus, the company announced in a news release.
If approved, practitioners would be able to experience and observe MDMA-assisted therapy sessions to further their understanding of psychedelic-assisted therapy. The trial would use clinical MDMA produced by Optimi, a Canadian-based drug manufacturer. Numinus intends to draw on volunteers through practitioners who have expressed interest through the organization’s practitioner training program and those practitioners who have previously completed the MAPS protocol training and meet the qualifications to enroll in Numinus’ MDMA-Practical Applications course.
“Practitioners who complete our MDMA-assisted therapy education program, or have already completed previous MDMA-assisted therapy programs and are qualified to enroll in our Practical Applications course, would be able to apply to participate in the experiential clinical trial—enabling them to observe, deliver, and receive the therapeutic protocol as part of their training experience,” Numinus founder and CEO Payton Nyquvest said in the release.
As proposed, the trial would be conducted at Numinus’ clinics in Vancouver, British Columbia, Canada, and could be expanded to additional locations at a later date.
“Our 37-year journey to medicalize the therapeutic use of psychedelics has never been closer to a reality, and we’re thrilled to have Numinus as a partner in this work,” Rick Doblin, president and founder of MAPS, said in the release. “Experiential training is an important element of a practitioner’s training in many therapeutic modalities, and through this carefully controlled clinical trial, Numinus is supporting our shared goal of providing training to practitioners who may one day deliver psychedelic-assisted therapy to individuals who need it.”
Numinus Names CFO
In a separate announcement published on Wednesday, Numinus said it has appointed Nikhil Handa as its chief financial officer. Handa succeeds outgoing CFO John Fong, who is stepping down to focus on family health matters. Fong will remain involved with the company during a transitional period.
Most recently, Handa served as CFO of the Supreme Cannabis Company, where he led finance, investor relations, and corporate development. Handa is also credited with leading an organizational restructuring at Supreme and was responsible for executing a sale of the company to Canopy Growth Corporation.
References
